<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045653</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-009</org_study_id>
    <nct_id>NCT03045653</nct_id>
  </id_info>
  <brief_title>Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer</brief_title>
  <official_title>Efficacy and Safety of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Endocrine Therapy Resisted Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Endocrine therapy is an effective and safe treatment for hormone receptor
      positive breast cancer. Unfortunately , endocrine treatment resistance occurs and there is an
      urgent need for treatment alternative. Laboratory researches and clinical case reports
      indicate that hormone receptor-high expressed breast cancer patients may potentially benefit
      from high-dose Tamoxifen or high-dose Tamoxifen plus chemotherapy , providing a new option
      for treatment strategy.

      Aim: To explore the efficacy and safety of high-dose Tamoxifen to standard hormone
      receptor-high expressed endocrine therapy resisted breast cancer.

      Methods: Eligible patients will be treated with tamoxifen 100 mg/d or high-dose Tamoxifen(100
      mg/d ) plus chemotherapy. Blood and tumor samples will be obtained from the patients.Evaluate
      curative effect every 3 months.

      Primary endpoint: progression-free survival (PFS). Secondary endpoints: objective response
      rate (ORR), clinical benefit rate (CBR), overall survival (OS) and safety.

      Exploratory endpointsincluded the efficacy predictive value of the 18F-FES SUVmax.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">February 21, 2019</completion_date>
  <primary_completion_date type="Actual">February 21, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>36months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Breast Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving a treatment of tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen Oral Product</intervention_name>
    <description>Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Female ≥ 18 years, ≤70 years. ECOG 0-1 with no deterioration over previous 2 weeks
        Minimum life expectancy 3 months Histological confirmation of hormone receptor-high
        expressed breast cancer(IHC:ER ≥60% and PR≥60%) on primary tumour at diagnosis/on biopsy of
        metastasis Histological confirmation of HER2 negative breast cancer on primary tumour at
        diagnosis/on biopsy of a metastasis The disease-free time of relapsed patients is more than
        12 months Once received standard hormone treatment and progressed Clinical or histological
        confirmation of metastatic or locally advanced disease not amenable to curative surgical
        resection At least one evaluative focus according to RECIST creterion or non-measurable
        disease but only bone metastasis Adequate bone marrow and organ function Progressive
        disease whilst receiving endocrine therapy for locally advanced or metastatic BC or
        relapsed with metastatic disease whilst receiving endocrine therapy Radiological or
        objective clinical evidence of recurrence or progression on or after last systemic therapy
        prior to enrolment

          -  4 prior lines of endocrine therapy for ABC

          -  3 line of cytotoxic chemotherapy for ABC Suitable for further endocrine therapy
             Availability of archival tumour sample or fresh biopsy Informed consent Normal organ
             function

        Exclusion Criteria:

          -  Last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour
             embolisation &lt;21 days prior to study treatment Last dose of palliative radiotherapy &lt;7
             days prior to study treatment Rapidly progressive visceral disease not suitable for
             further endocrine therapy Spinal cord compression or brain/meningeal metastases unless
             asymptomatic, treated and stable and not requiring steroids for ≥ 4 weeks study
             treatment Creatinine clearance &lt;30 ml/min. Patients with creatinine clearance &lt;50
             mL/min will start at a permanently reduced vandetanib dose of 200 mg.

        Major surgery (excluding placement of vascular access) within 4 weeks before study
        treatment Evidence of severe or uncontrolled systemic diseases, including uncontrolled
        hypertension, active bleeding diatheses, or active infection including hepatitis B,
        hepatitis C and HIV With the exception of alopecia, any unresolved toxicities from previous
        therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone
        metastasis Evidence of dementia, altered mental status or any psychiatric condition that
        would prohibit understanding or rendering of informed consent Participation in another
        study with investigational product during last 30 days Inability or unwillingness to comply
        with study procedures, including inability to take regular oral medication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongyu Yuan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun-yatsen University Cancer center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University, Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <results_first_submitted>September 12, 2019</results_first_submitted>
  <results_first_submitted_qc>September 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2019</results_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhong-yu Yuan</investigator_full_name>
    <investigator_title>professer</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>high dose Tamoxifen</keyword>
  <keyword>endocrine therapy</keyword>
  <keyword>Hormone Receptor Positive Malignant Neoplasm of Breast</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Breast Cancer Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03045653/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm</title>
          <description>receiving a treatment of tamoxifen 100 mg/d</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>receiving a treatment of tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
Tamoxifen Oral Product: Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="27" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <time_frame>36months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>receiving a treatment of tamoxifen 100 mg/d</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2.6" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm</title>
          <description>receiving a treatment of tamoxifen 100 mg/d</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Zhongyu Yuan</name_or_title>
      <organization>Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative innovation center for Cancer Medicine</organization>
      <phone>+8613798027658</phone>
      <email>yuanzhy@sysucc.org.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

